Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Regenerative Engineering and Translational Medicine is Scopus-indexed (Q2, CiteScore 4.9), WoS ESCI. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer Science and Business Media Deutschland GmbH.
Checked against the index lists dated .
ISSN 2364-4133Verify ISSN ↗2364-4141Verify ISSN ↗
Publisher: Springer Science and Business Media Deutschland GmbH
Cost to publish: About US$3,090 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Medicine (miscellaneous) | 125 / 466 | 73rd | Q2 |
| Biomedical Engineering | 156 / 342 | 54th | Q2 |
| Biomaterials | 79 / 146 | 46th | Q3 |
| Cell Biology | 180 / 289 | 37th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2015–present, best quartile Q2, CiteScore 4.9.
Regenerative Engineering and Translational Medicine is Q2 in Medicine (miscellaneous) (rank 125 of 466), Q2 in Biomedical Engineering (rank 156 of 342) and Q3 in Biomaterials (rank 79 of 146), by CiteScore 2025. It is ranked in 4 subject areas in all.
Regenerative Engineering and Translational Medicine is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.9, which places it in quartile Q2 at the 73rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.533, quartile Q2, with an H-index of 31.
The publisher lists an article processing charge of about US$3,090 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Regenerative Engineering and Translational Medicine is published by Springer Science and Business Media Deutschland GmbH. Its print ISSN is 2364-4133 and its online ISSN is 2364-4141.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Emerging Sources Citation Index.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Regenerative Engineering and Translational Medicine has an h-index of 36 and a 2-year mean of 2.48 citations per paper (OpenAlex). Its Scopus CiteScore is 4.9, quartile Q2. On 2-year citations it ranks #127 of 451 Scopus journals in Medicine (miscellaneous).
Regenerative Engineering and Translational Medicine published 150 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 95 research articles (2025–2026), authors are most often from India (44.4%), Iran (20.4%) and United States (8.9%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.